医学
细胞因子
细胞激素风暴
疾病
免疫学
白细胞介素6
炎症
细胞因子释放综合征
缺氧(环境)
白细胞介素
封锁
低氧血症
2019年冠状病毒病(COVID-19)
受体
内科学
传染病(医学专业)
氧气
化学
有机化学
作者
Jamal Majidpoor,Keywan Mortezaee
标识
DOI:10.1016/j.biopha.2021.112419
摘要
Interleukin-6 (IL-6) is a multi-tasking cytokine that represents high activity in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and cancer. High concentration of this pleiotropic cytokine accounts for hyperinflammation and cytokine storm, and is related to multi-organ failure in patients with SARS-CoV-2 induced disease. IL-6 promotes lymphopenia and increases C-reactive protein (CRP) in such cases. However, blockade of IL-6 is not a full-proof of complete response. Hypoxia, hypoxemia, aberrant angiogenesis and chronic inflammation are inter-related events occurring as a response to the SARS-CoV-2 stimulatory effect on high IL-6 activity. Taking both pro- and anti-inflammatory activities will make complex targeting IL-6 in patient with SARS-CoV-2 induced disease. The aim of this review was to discuss about interactions occurring within the body of patients with SARS-CoV-2 induced disease who are representing high IL-6 levels, and to determine whether IL-6 inhibition therapy is effective for such patients or not. We also address the interactions and targeted therapies in cancer patients who also have SARS-CoV-2 induced disease.
科研通智能强力驱动
Strongly Powered by AbleSci AI